International AIDS Society

The Sydney Declaration:
Good Research Drives Good Policy and Programming
- A Call to Scale Up Research

4th IAS Conference on Pathogenesis, Treatment and Prevention
22 – 25 July 2007
Sydney, Australia

Ten per cent of all resources dedicated to HIV programming should be used for research towards optimizing interventions utilized and health outcomes achieved.

The evolution of HIV prevention, treatment, and care over the past quarter century is one of the great successes of medical science. Committed and sustained research efforts have provided the evidence on which approaches to programming are based. These same scientific efforts are now resulting in new prevention technologies and drugs, and new strategies to manage and deliver both. Good research drives good policy.

In recent years resources have dramatically increased for delivery of existing interventions in resource-limited settings. Although funding remains insufficient to meet the increasing need for services, it is imperative that the global community does not lose sight of the future while responding to the immediate crisis. An effective response to HIV/AIDS requires a sustained commitment to ensure that interventions and approaches to service delivery are continuously improved over time. For example, as current first-line antiretroviral regimens become increasingly available in resource-limited settings, there is an urgent need to identify optimum, durable, and well-tolerated standardised first-line and second-line regimens, and to monitor and respond to resistance patterns as they emerge. Outcomes will not necessarily be the same in diverse settings across the globe.

Operations research is critical, in addition to basic, clinical, prevention, social, and policy research. We must identify which approaches are effective in the field, which are not, and why. We must also learn how to integrate HIV-specific services with primary, tuberculosis, malaria, prenatal and postnatal, and sexual and reproductive health services. None of these services have been as effectively linked to scale-up of HIV programming as is possible or necessary. Furthermore, greater understanding of the social, political, and cultural barriers that perpetuate stigma and discrimination can contribute to ensuring that governments act in the interests of public health.

Operations research will enable rapid implementation of new technologies to prevent, diagnose, and treat HIV infection, and can help to ensure that health systems are strengthened as a result of scaling-up HIV prevention, treatment, and care. Unfortunately, few granting agencies or national health budgets commit designated funds to operations research, and where such funding is available, it is often underused. The Global Fund to Fight AIDS, Tuberculosis and Malaria, for example, allows up to 10% of each grant to be allocated for operations research, but this provision is rarely used by countries and the research community is rarely represented on Country Coordinating Mechanisms (CCMs). The lack of participation on CCMs further reduces the likelihood that operations research will be a priority in funding applications.

An ancillary benefit of integrating research into the overall approach to scale-up in the developing world will be an expanding cadre of health-care workers trained in research methodologies and practice. Such research should not be seen as an additional burden on the various funding bodies or ministries of health but, on the contrary, as the only means by which we can refine our understanding of what is and is not effective.

Last but not least, all areas of research can further strengthen the efforts of the global AIDS community to confront the absurd theories of AIDS denialists as well as the “magic” cures that continue to confuse policymakers, health-care professionals, and communities of people at risk of and living with HIV/AIDS throughout the world. HIV professionals must continuously build on the evidence base to ensure sound and effective policies and practices in HIV/AIDS prevention, treatment, and care.

The undersigned individuals and organisations call on national governments and bilateral, multilateral, and private donors to allocate 10% of all resources for HIV programming to research. We believe that without such funding we will fail to maintain a sustained and effective response to the AIDS pandemic.

First Name(s):
  Last Name(s):
Organization Name:

#First nameLast nameOrganizationCountry
1. DavidCooperLocal Chair, 4th IAS Conference on Pathogenesis, Treatment and Prevention, University of New South WalesAustralia
2. PedroCahnPresident, International AIDS Society, Chair, 4th IAS Conference on Pathogenesis, Treatment and Prevention, Fundacion HuespedArgentina
3. SharonLewinDeputy Local Chair, 4th IAS Conference on Pathogenesis, Treatment and Prevention, Monash University & The Alfred HospitalAustralia
4. JohnKaldorDeputy Local Chair, 4th IAS Conference on Pathogenesis, Treatment and Prevention, University of New South WalesAustralia
5. CraigMcClureInternational AIDS SocietySwitzerland
6. RodneyKortInternational AIDS SocietySwitzerland
7. MarkBoydUniversity of New South WalesAustralia
8. DennisAltmanLaTrobe University, MelbourneAustralia
9. FrançoiseBarré-SinoussiRegulation of Retroviral Infections Unit, Institut PasteurFrance
10. BonaventuraClotetFundacio Irsi Caixa, Hospital Universitari Germans Trias i PujoSpain
11. HoosenCoovadiaDoris Duke Medical Research Institute, University of KwaZulu-Natal, DurbanSouth Africa
12. RicardoDiazInfectious Diseases Division, Paulista School of Medicine, Federal University of Sao PauloBrazil
13. JoelGallantJohns Hopkins University School of Medicine & Johns Hopkins Bloomberg School of Public HealthUnited States
14. HeleneGayleCARE USAUnited States
15. AndrzejHorbanHospital of Infectious Diseases, WarsawPoland
16. AikichiIwamotoInstitute of Medical Science, University of Tokyo & Division of Infectious Diseases, Advanced Clinical Research Center, IMSUTJapan
17. EllyKatabiraInfectious Diseases Institute, Makerere University Medical SchoolUganda
18. MichelKazatchkineGlobal Fund to Fight AIDS, Tuberculosis and MalariaFrance
19. SukhonthaKongsinFaculty of Public Health, Mahidol University, BangkokThailand
20. IvetteLorenzana de RiveraDepartment of Microbiology, National University of HondurasHonduras
21. JulioMontanerPresident-Elect, International AIDS Society, St. Paul’s Hospital & University of British ColumbiaCanada
22. ViolaOnwuliriDepartment of Biochemistry, University of JosNigeria
23. HectorPerezInfectious Diseases Unit, Juan A Fernandez HospitalArgentina
24. CelsoRamos FilhoDepartment of Preventive Medicine, Federal University of Rio de JaneiroBrazil
25. PeterReissAcademic Medical Centre, University of Amsterdam & International Antiviral Evaluation CenterNetherlands
26. NajmusSadiqUnited Nations Development Programme (UNDP) Country OfficeBangladesh
27. NMSamuelTamil Nadu Dr. M.G.R. Medical University, ChennaiIndia
28. CherylSmithNorth General Hospital & Mount Sinai School of MedicineUnited States
29. LuisSoto-RamirezMolecular Virology Unit, Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y NutricionMexico
30. SheilaTlouMinistry of HealthBotswana
31. SharonWalmsleyUniversity Health Network, Toronto General Hospital & Department of Medicine, University of TorontoCanada
32. IanWellerCentre for Sexual Health & HIV Research at University College LondonUnited Kingdom
33. AlanWhitesideHealth and Economics and HIV/AIDS Research Division, University of KwaZulu-Natal, DurbanSouth Africa
34. LevinaCrooksAustralasian Society for HIV MedicineAustralia
35. SuzanneCrowePathogenesis and Clinical Research Programme, Burnet InstituteAustralia
36. Paul R.GorryMacfarlane Burnet Institute for Medical Research and Public HealthAustralia
37. GuidoPoliSan Raffaele Scientific InstituteItaly
38. AlanLandayRush University Medical CentreAustralia
39. RobertBadaroFederal University of BahiaBrazil
40. GloriaEcheverria de PerezImmunology Institute, Faculty of Medicine, Central University of VenezuelaVenezuela
41. Adeeba bteKamarulzamanUniversity of MalaysiaMalaysia
42. CeciliaCheng-MayerAaron Diamond AIDS Research Center, Rockefeller UniversityUnited States
43. MarkWainbergMcGill University AIDS CentreCanada
44. RoyChanAction for AIDS Singapore
45. IanGustUniversity of MelbourneAustralia
46. ThomasKerrBC Centre for Excellence in HIV/AIDSCanada
47. DouglasRichmanUniversity of California San DiegoUnited States
48. SouleymaneMboupUniversite Cheikh Anta DIOP, DakarSenegal
49. RonaldMitsuyasuUCLA Center for Clinical AIDS Research and Education, David Geffen School of Medicine, UCLAUnited States
50. WilliamPowderlyUCD School of Medicine and Medical Science, Health Sciences Centre, BelfieldIreland
51. VinodPandeyAmerican Academy of Pediatrics, Nchanga South HospitalZambia
52. John P.MooreJoan and Sanford I Weill Medical College, Cornell University, Department of Microbiology and ImmunologyUnited States
53. JamesMcIntyrePerinatal HIV Research Unit, University of the WitwatersrandSouth Africa
54. Kuan-TheJeangMolecular Virology Section, NIAID/NIHUnited States
55. Jean-PaulMoattiUniversity of the Mediterranean, Research Institute on Social Sciences Applied to Health of Aix-Marseille (IFR SHESS-AM), Social Sciences Committee of ANRS (French Agency of AIDS Research), Advisory Committee on Health Research of the World Health OrganizFrance
56. JoepLangeCenter for Poverty-related Communicable Diseases, Academic Medical Center, University of AmsterdamNetherlands
57. AndrewBallDepartment of HIV/AIDS, World Health OrganizationSwitzerland
58. TonyKelleherImmunovirology and Pathogenesis Programme, NCHECR, UNSW, Centre for Immunology, St.Vincent’s HospitalAustralia
59. DamianPurcellMolecular Virology Laboratory Department of Microbiology  and Immunology, University of MelbourneAustralia
60. MartynFrenchDepartment of Clinical Immunology, Royal Perth HospitalAustralia
61. Jose M.GatellInfectious Diseases & AIDS Unit, Clinical Institute of Medicine & Dermatology, Hospital Clinic, University of BarcelonaSpain
62. DanielKuritzkesHarvard Medical School, Brigham and Women’s HospitalUnited States
63. MatsAhnlundInternational AIDS SocietySwitzerland
64. KennethMayerBrown University, Genway Community HealthUnited States
65. Patrick NwanzeOkohDelta State University,AbrakaNigeria
66. StefanoVellaDipartimento del Farmaco, The Italian National Institute of HealthItaly
67. LazareKaptueUniversité des Montagnes (UdM), BangangtéCameroon
68. Dr NKumarasamyYRGCARE,VHS, ACTG-International Clinical Trials Unit,Chennai siteIndia
69. JenniferHoyTrack B Co-Chair, IV IAS Conference on Pathogenesis, Treatment and PreventionAustralia
70. JosephineOkumuPositive African Mutual AidNetherlands
72. AmyReesMurdoch University, PerthAustralia
73. shivajijadhavNIRRH ICMRIndia
74. SHIVAJIJADHAVNational Institute for Research in Reproductive Health IMCR India
75. A HbandivdekarNIRRH ICMRIndia
76. SistoSánchezAmnistie internationale, réseau LGBT-Canada/CPAVIHCanada
77. Bright LabanWaswaAIDS Information Centre-UgandaUganda
78. MilindBhrushundiLata mangeshkar Hospital NagpurIndia
79. DiegoCecchiniFUNCEIArgentina
80. MuganziAlex MugangaInfectious Diseases Institute, Makerere University, KampalaUganda
81. Margaret Kestin Nkechinyerem OhuajahHiv/Aids Control Agency(HACA)Nigeria
82. PolladachTHEERAPAPPISITThe University of Western SydneyAustralia
83. KarenBennettInternational AIDS SocietySwitzerland
84. FranklinUdahSociety for AIDS in Nigerian UniversitiesNigeria
85. SukhumJiamtonFaculty of Medicine, Siriraj Hospital, Mahidol UniversityThailand
86. Robert MitchellNAPWAAustralia
87. John DayeNAPWAAustralia
88. BillWhittakerNAPWA Australia
89. JoWatsonNAPWAAustralia
90. Isobel MaryPoyntenNational Centre in HIV Epidemiology and Clinical Research, UNSWAustralia
91. NijuMuhammedLailapariyaram Medical CollegeIndia
92. BernardHirschelGeneva University HospitalSwitzerland
93. Charles Chinonye UgwuekeHiv/Aids Control Agency(HACA)Nigeria
94. DongliLiChina Population and Development Research CenterChina
95. Ranjith KumarYalamanchiliOsmania Medical collegeIndia
97. MarcelMizerofaculty of medicine, ngozi BurundiBurundi
98. ShinichiOkaInternational Medical Center of JapanJapan
99. JialunZhouNational Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, SydneyAustralia
100. ThiraSirisanthanaChiang Mai UniversityThailand
12345678910...Last page >>